Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Fas Ligand/FasL Protein, 1mg  

Recombinant Human Fas Ligand/FasL Protein, 1mg

Recombinant Human Fas Ligand /FasL Protein (rhFas Ligand ) Pro 134 - Leu 281 was produced in human 293 cells (HEK293).

Synonym
recombinant human protein,FASLG, ALPS1B, APT1LG1, CD178, CD95-L, CD95L, FASL, TNFSF6, Fas ligand

More details

FAL-H5241-1K

Availability: within 7 days

3 100,00 €

Background
Fas ligand also known as FasL, CD178, CD95L, or TNFSF6, is a homotrimeric type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its binding with its receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain. Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Apoptosis triggered by Fas-Fas ligand binding plays a fundamental role in the regulation of the immune system. Its functions include:T-cell homeostasis, cytotoxic T-cell activity, immune privilege, maternal tolerance, tumor counterattack. Defective Fas-mediated apoptosis may lead to oncogenesis as well as drug resistance in existing tumors. Germline mutation of Fas is associated with autoimmune lymphoproliferative syndrome (ALPS), a childhood disorder of apoptosis.[1-3]

Source
Recombinant Human Fas Ligand /FasL Protein (rhFas Ligand ) Pro 134 - Leu 281(Accession # AAH17502.1) was produced in human 293 cells (HEK293).

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 17.7 kDa. The protein migrates as 25-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhFasL by the LAL method.

Purity
>95% purity as determined by SDS-PAGE of reduced rhFasL.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human Fas Ligand, His Tag (Catalog # FAL-H5241) at 5μg/mL (100 μL/well) can bind Human Fas, Fc Tag (Catalog # FAS-H5252) with a linear range of 1.56-12.5 ng/mL.

References

(1) Sheikh MS, Fornace AJ., 2000, Leukemia 14 (8): 1509–1513.
(2) Andersen MH, et al., 2006, J. Invest. Dermatol. 126 (1): 32–41.
(3) Igney FH, Krammer PH., 2005, Cancer Immunol. Immunother. 54 (11): 1127–1136.